FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2082391499> ?p ?o ?g. }

• W2082391499 endingPage "1547" @default.
• W2082391499 startingPage "1543" @default.
• W2082391499 abstract "Bisphosphonate pharmacokinetics may affect individual responses. Skeletal retention of pamidronate infused monthly to patients with bone metastases was highly variable (12-98%) and did not diminish with time, showing the capacity of the skeleton to retain large amounts of bisphosphonate. Relationships between skeletal retention of pamidronate and rate of bone resorption are complex and depend on previous treatment and the total amount of retained bisphosphonate.Bisphosphonates (BPs) given intravenously every 3-4 weeks are effective in the management of metastatic bone disease from breast cancer, but responses among patients vary, and it is not known whether current dose and dose intervals are appropriate for an individual patient. An influence of pharmacokinetics of BPs on antiresorptive action may contribute to this variation in response. To test this hypothesis, we determined the skeletal retention of intravenous pamidronate and its association to the rate of bone resorption in patients with bone metastases from breast cancer.In a cross-sectional study, 24-h urinary excretion of pamidronate and the biochemical marker of bone resorption N-terminal telopeptide of type 1 collagen and serum alkaline phosphatase were measured in 40 patients with bone metastases from breast cancer at the beginning, after 3-6 months, and after 1 year of treatment with intravenous pamidronate 90 mg every 3-4 weeks.Skeletal retention (dose--amount excreted into urine) 2 days after infusion varied between 12% and 98% (mean, 62%) of the administered dose, but there were no differences in retention between patients receiving pamidronate for the first time or after 3-6 months or after 1 year of treatment. Retention of pamidronate was related to the prevalent rate of bone turnover in previously untreated patients, whereas no such relationship was found in previously treated patients. Rate of bone resorption after treatment seemed to be related to the amount of pamidronate retained. During 1 year of treatment, retention of pamidronate remained constant, indicating no saturation of skeletal binding sites with treatment. The variability in retention among individual patients can be attributed to the number of available binding sites. This is related, however, to bone turnover only before the start of treatment. The apparent relationships between skeletal retention and antiresorptive effect could have implications for the design of optimal therapeutic regimens with BPs in patients with bone metastases from breast cancer." @default.
• W2082391499 created "2016-06-24" @default.
• W2082391499 creator A5008043617 @default.
• W2082391499 creator A5011081386 @default.
• W2082391499 creator A5025935523 @default.
• W2082391499 creator A5053553198 @default.
• W2082391499 creator A5057643841 @default.
• W2082391499 creator A5073406580 @default.
• W2082391499 creator A5078372826 @default.
• W2082391499 creator A5090644978 @default.
• W2082391499 date "2005-09-01" @default.
• W2082391499 modified "2023-10-09" @default.
• W2082391499 title "Skeletal Retention of Bisphosphonate (Pamidronate) and Its Relation to the Rate of Bone Resorption in Patients With Breast Cancer and Bone Metastases" @default.
• W2082391499 cites W1973947102 @default.
• W2082391499 cites W1990711952 @default.
• W2082391499 cites W1994414479 @default.
• W2082391499 cites W2002074462 @default.
• W2082391499 cites W2032919208 @default.
• W2082391499 cites W2072789990 @default.
• W2082391499 cites W2072797307 @default.
• W2082391499 cites W2076769374 @default.
• W2082391499 cites W2085542215 @default.
• W2082391499 cites W2089847814 @default.
• W2082391499 cites W2095170176 @default.
• W2082391499 cites W2159100092 @default.
• W2082391499 cites W2288888750 @default.
• W2082391499 cites W2316096113 @default.
• W2082391499 cites W2783103906 @default.
• W2082391499 doi "https://doi.org/10.1359/jbmr.050522" @default.
• W2082391499 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16059626" @default.
• W2082391499 hasPublicationYear "2005" @default.
• W2082391499 type Work @default.
• W2082391499 sameAs 2082391499 @default.
• W2082391499 citedByCount "45" @default.
• W2082391499 countsByYear W20823914992012 @default.
• W2082391499 countsByYear W20823914992013 @default.
• W2082391499 countsByYear W20823914992016 @default.
• W2082391499 countsByYear W20823914992017 @default.
• W2082391499 countsByYear W20823914992018 @default.
• W2082391499 countsByYear W20823914992019 @default.
• W2082391499 countsByYear W20823914992020 @default.
• W2082391499 crossrefType "journal-article" @default.
• W2082391499 hasAuthorship W2082391499A5008043617 @default.
• W2082391499 hasAuthorship W2082391499A5011081386 @default.
• W2082391499 hasAuthorship W2082391499A5025935523 @default.
• W2082391499 hasAuthorship W2082391499A5053553198 @default.
• W2082391499 hasAuthorship W2082391499A5057643841 @default.
• W2082391499 hasAuthorship W2082391499A5073406580 @default.
• W2082391499 hasAuthorship W2082391499A5078372826 @default.
• W2082391499 hasAuthorship W2082391499A5090644978 @default.
• W2082391499 hasConcept C121608353 @default.
• W2082391499 hasConcept C125870589 @default.
• W2082391499 hasConcept C126322002 @default.
• W2082391499 hasConcept C126894567 @default.
• W2082391499 hasConcept C131075544 @default.
• W2082391499 hasConcept C134018914 @default.
• W2082391499 hasConcept C146562846 @default.
• W2082391499 hasConcept C160160445 @default.
• W2082391499 hasConcept C170033053 @default.
• W2082391499 hasConcept C181199279 @default.
• W2082391499 hasConcept C185592680 @default.
• W2082391499 hasConcept C2776169692 @default.
• W2082391499 hasConcept C2776541429 @default.
• W2082391499 hasConcept C2777251235 @default.
• W2082391499 hasConcept C530470458 @default.
• W2082391499 hasConcept C55493867 @default.
• W2082391499 hasConcept C673006 @default.
• W2082391499 hasConcept C71924100 @default.
• W2082391499 hasConceptScore W2082391499C121608353 @default.
• W2082391499 hasConceptScore W2082391499C125870589 @default.
• W2082391499 hasConceptScore W2082391499C126322002 @default.
• W2082391499 hasConceptScore W2082391499C126894567 @default.
• W2082391499 hasConceptScore W2082391499C131075544 @default.
• W2082391499 hasConceptScore W2082391499C134018914 @default.
• W2082391499 hasConceptScore W2082391499C146562846 @default.
• W2082391499 hasConceptScore W2082391499C160160445 @default.
• W2082391499 hasConceptScore W2082391499C170033053 @default.
• W2082391499 hasConceptScore W2082391499C181199279 @default.
• W2082391499 hasConceptScore W2082391499C185592680 @default.
• W2082391499 hasConceptScore W2082391499C2776169692 @default.
• W2082391499 hasConceptScore W2082391499C2776541429 @default.
• W2082391499 hasConceptScore W2082391499C2777251235 @default.
• W2082391499 hasConceptScore W2082391499C530470458 @default.
• W2082391499 hasConceptScore W2082391499C55493867 @default.
• W2082391499 hasConceptScore W2082391499C673006 @default.
• W2082391499 hasConceptScore W2082391499C71924100 @default.
• W2082391499 hasIssue "9" @default.
• W2082391499 hasLocation W20823914991 @default.
• W2082391499 hasLocation W20823914992 @default.
• W2082391499 hasOpenAccess W2082391499 @default.
• W2082391499 hasPrimaryLocation W20823914991 @default.
• W2082391499 hasRelatedWork W2017130844 @default.
• W2082391499 hasRelatedWork W2044981350 @default.
• W2082391499 hasRelatedWork W2060746944 @default.
• W2082391499 hasRelatedWork W2093741838 @default.
• W2082391499 hasRelatedWork W2100834596 @default.
• W2082391499 hasRelatedWork W2114367477 @default.
• W2082391499 hasRelatedWork W2132711769 @default.

• next